Eye disease biobank seeks clues to uveitis
NCT ID NCT02656381
First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 4 times
Summary
This study collected blood, saliva, and eye fluid samples from 343 people with uveitis, an inflammatory eye disease that can cause vision loss. Researchers aimed to learn which genes and other factors might lead to the disease and affect treatment response. Participants were followed for up to 10 years with regular eye exams and tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
343 people
The number who actually took part.
- Started
-
Jul 2016
- Finished
-
May 2023
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study plans to accrue 550 participants with uveitis or related diseases. This will not be restricted by anatomical location or etiology with the inclusion of both idiopathic cases, infectious uveitis, scleritis and those cases linked to a disease known to be associated with an increased risk of intraocular inflammation (e.g., sarcoidosis, Beh(SqrRoot)(Beta)et's disease, multiple sclerosis (MS) and lymphoma). In addition, 100 participants without intraocular inflammatory disease will be enrolled as controls.
- Ages
-
8 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA (NOT APPLICABLE TO COVID COHORT): Participants will be eligible if they: 1. Have a diagnosis of uveitis, scleritis or a disease known to be associated with intraocular inflammation, (e.g., sarcoidosis, Behcet's disease, MS and lymphoma) OR could serve as an unaffected control. 2. Are eight years of age or older if an affected participant. 3. Are 18 years of age or older if serving as an unaffected control. 4. For participants 18 years of age and older: * Are willing to give informed consent that includes collection and study of at least one peripheral blood sample. EXCLUSION CRITERIA (NOT APPLICABLE TO COVID COHORT): Participants will not be eligible if they: 1. Are unable to understand and sign the informed consent form. 2. Are unable or unwilling to give informed consent that includes use of medical records and clinical samples for current and future research related to vision and diseases affecting the eyes. 3. Have a systemic disease that compromises the ability to provide adequate ophthalmologic examination or treatment as determined by the investigator. 4. For participants with uveitis: * Have inactive anterior uveitis or quiescent infectious uveitis not requiring such regimented and intensive standardized testing as determined by the Investigator. * Have end stage or chronic quiescent changes in the setting of an established infectious etiology, such as an old ocular toxoplasma scar (participants with active intraocular inflammation due to infection will be recruited). The eligibility requirements for this protocol are intended to be broadly inclusive, but those individuals screened at the NEI and found to be ineligible may be evaluated under the NEI Screening Protocol for potential participation in other studies. INCLUSION CRITERIA FOR COVID-19 COHORT: Participants with COVID-19 will be eligible if they: 1. Have a diagnosis of COVID-19 confirmed by a nasopharyngeal swab (or another confirmative test) within less than or equal to 3 days prior, with symptoms of any severity. 2. Are able to give verbal consent. 3. Are 16 years of age or older. EXCLUSION CRITERIA FOR COVID-19 COHORT: Participants with COVID-19 will not be eligible if they: 1. Use regular prescription eye drops on the day of sampling. 2. Current use of antiviral medications.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID -19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise rebuild muscle and balance in MS?
- Can diet ease the crushing fatigue of multiple sclerosis?
- One-Time CAR-T infusion tested against progressive MS
- Can PET scans reveal hidden brain inflammation in MS?
- Home antibody tests put to the test: can you read your own COVID-19 result?
- Can a pill rebuild the Brain's insulation? MS trial puts remyelination to the test